A clinical trial testing Duchenne gene-editing therapy candidate PBGENE-DMD will soon launch in the U.S., having won clearance from the FDA.
PBGENE-DMD is Precision's wholly-owned, first-in-class in vivo gene editing program utilizing a gene excision approach intended to permanently correct the dystrophin gene in patients with mutations ...
Shares of Dyne Therapeutics, Inc. DYN, a clinical-stage muscle disease company, tumbled 30.7% on two key announcements. The company announced that some of its senior executives have stepped down from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results